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INTRODUCTION
Galectins are a family of carbohydrate-binding
proteins characterized by a conserved amino acid
sequence defined by structural similarities in their
carbohydrate-binding domain and affinity for β-
galactoside-containing glycoconjugates. It was re-
ported that galectins play a significant role in apopto-
sis, several of which, such as galectin-1 and galectin-
9, were implicated in the promotion of apoptosis of
immune and melanoma cells, respectively, whereas
galectin-7 induces apoptosis of colon cancer cells. In
contrast, galectin-3 was reported to be an antiapop-
totic molecule, inhibiting Fas-induced T-cell apop-
tosis as well as epithelial cell apoptosis induced by
staurosporine, cisplatin, genistein, and anoikis (1).
Galectin-3 is isolated as a 32 kDa monomer, and
consists of three distinct structural domains : the
carboxyterminal domain, which appears as the
carbohydrate-recognition domain, the N-terminal
domain, comprising the 20 NH2-terminal residues,
and the R domain, composed of Pro-Gly-Tyr-rich re-
peating motif (2). Galectin-3 contains the Asp-Trp-
Gly-Arg (NWGR) motif in the C-terminal domain,
and it doesn’t exist in other galectins. The NWGR
motif is critical for the anti-apoptotic function of
galectin-3 (3).
Galectin-3 is expressed in normal and neoplastic
cells (4). Galectin-3 is localized not only in intracel-
lular space such as the cytoplasm or the nucleus but
also in extracellular space such as the cell surface or
the extracellular matrix (5).
In certain types of cancers, the expression of
galectin-3 is positively correlated to tumor progres-
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sion, such as gastric cancer (6), liver cancer (7),
thyroid cancer (8). In other types of cancers, it is
inversely correlated to tumor progression, such as
head and neck cancer (9), uterine sarcoma (10),
breast cancer (11), pancreas cancer (12).
In bladder cancer, galectin-3 mRNA levels were
increased in most tumors compared with normal
urothelium (13). However, the clinical relevance of
this finding is not fully understood. We examined
serum level of galectin-3 in patients with bladder
cancer.
PATIENTS AND METHODS
Measurement of serum galectin-3 concentration
We studied serum samples of 67 patients who
were admitted for urological diseases at our insti-
tution between 1996 and 2006. We classified these
67 patients into the cancer group (n=43) and the
control group (n=24). Control group consisted of
patients with 21 urolithiasis, 1 varicocele and 2
stress incontinence. Clinical data are described in
Table 1.
All serum samples were stored at -80until this
study. All samples were returned to room tempera-
ture before use. Serum galectin-3 concentration was
measured by ELISA in accordance with the manu-
facture’s instructions (Human Galectin-3 Assay Kit,
IBL). Measurable range of this ELISA is from
117.19 to 7500 pg/ml. This ELISA kit has been de-
scribed and validated elsewhere.
Immunohistochemical staining
After radical cystectomy, both bladder cancer tis-
sue and normal bladder tissue were embedded in
OCT compound and stored at -80. We selected
the patient with high serum galectin-3 concentra-
tion, and cut these tissue in thickness of 5 microme-
ters at -18and put section on the slide. We per-
formed hematoxylin eosin staining, and chose the
section by which a core is stained clearly. The good
bladder cancer tissue and normal bladder tissue
could be obtained. The histopathological diagnosis
of selected bladder cancer tissue was urothelial car-
cinoma (UC), G3, pT3a pN0M0.
Immunohistochemical staining was performed
with the VECTASTAIN ABC (Avidin Biotinylated
enzyme Complex) system. The brief procedure was
as follows. Sections were air dried, and fixed with
acetone. We rinsed sections in tap water and washed
in buffer. After incubating sections for 30 minutes
with diluted normal blocking serum, the primary
antibody (rat monoclonal anti-Gal-3 antibody, TIB
166) was incubated for 60 minutes at room tem-
perature. Following incubation for 30 minutes with
diluted biotinylated secondary antibody solution, we
added VECTASTAIN ABC Reagent and waited for
30 minutes at room temperature. We incubated sec-
tions in peroxidase substrate solution until desired
stain intensity develops. Cancer tissue and normal
tissue were stained for the same hour at the same
time. The expression of galectin-3 was evaluated us-
ing light microscopy at400 magnification and the
results interpreted according to the intensity of im-
munoreactive product in the bladder cancer cells.
The immunohistochemical results were evaluated
as : weak, less than 20% positive cells with weak in-
tensity ; moderate, 20-50% positive cells with mod-
erate intensity ; and strong, more than 50% positive
cells with strong intensity.
Statistical analysis
Statistical analysis was performed using SPSS-
II. To compare results of measurement of serum
galectin-3 concentration in two groups, we used
Mann-Whitney test. Differences were considered
significant at p0.05.
RESULTS
Serum level of galectin-3
Serum galectin-3 concentration was increased in
the cancer group. Median value of serum galectin-3
concentration was 1068 pg/ml (range 551-2028)
in the cancer group vs. 584 pg/ml (range 259-1262)
in controls (p0.0005, Fig. 1A). We divided 43 blad-
der cancer patients into 33 non muscle invasive
group and 10 muscle invasive group, and examined
these samples. There was no significant difference
Table 1. Patient’s clinical data
cancer group controls
n 43 24
mean age (range) 72 (45-83) 60 (28-85)
sex ratio M/F 34/9 12/12
non muscle invasion 33 -
muscle invasion 10 -
G1 2 -
G2 21 -
G3 20 -
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in serum galectin-3 concentration between the two
groups (Fig. 1B). We also divided these 43 patients
into 20 patients with G3 and 23 patients with G1 or
G2. There was no apparent correlation in serum
level of galectin-3 between the two groups (Fig. 1C).
Based on data from the patients with bladder cancer,
receiver operating characteristic (ROC) curve was
obtained. The ideal cutoff value of serum galectin-3
concentration was recommended to be 586 pg/ml.
Using this cutoff value, the sensitivity and specific-
ity were 97.7% and 54.2%, respectively.
Immunohistochemical staining of galectin-3
We selected one patient with high serum galectin-3
concentration, and studied immunohistochemical
staining of galectin-3 in bladder cancer tissue and
normal bladder tissue. The histopathological diag-
nosis of selected bladder cancer tissue was UC, G3,
pT3a pN0M0. Higher expression of galectin-3 was
observed in bladder cancer tissue than in normal
bladder tissue. The cytoplasm was stained strongly
in bladder cancer tissue, but almost no cytoplasm
was stained in normal tissue (Fig. 2). We performed
immunostaining of galectin-3 to other three sam-
ples (UC, G3, pT2b or pT3a pN0M0). We evaluated
all bladder cancer tissue as strong, and all normal
tissue as weak according to our criteria. There was
no correlation between the level of serum galectin-3
and degree of staining. The pattern of staining was
same as the above.
DISCUSSION
Galectin-3 is a member of the galectin gene fam-
ily that is expressed at elevated levels in a variety of
neoplastic cell types and has been associated with
cell growth, cellular adhesion process, cell prolif-
eration, transformation, metastasis, and apoptosis
(14-20). Galectin-3 has both anti-apoptotic and pro-
apoptotic function depending on cell’s differentia-
tion status and tissue type (21). It was reported that
A
B
C
Fig. 1. Analysis of serum galectin-3 concentration ; Serum
galectin-3 concentration of the cancer group was statistically
higher than that of controls (A). There was no apparent corre-
lation in galectin-3 concentration between non muscle invasive
group and muscle invasive group (B). No significant difference
was seen in galectin-3 concentration between G3 and G1 or G2
by Mann-Whitney test (C).
A B
Fig. 2. Immunohistochemical staining of galectin-3 ; Black
arrow indicates nucleus and white arrow indicates cytoplasm.
Higher expression of galectin-3 was observed in bladder cancer
tissue (B) than in normal bladder tissue (A). The cytoplasm was
stained strongly in bladder cancer tissue, but almost no cyto-
plasm was stained in normal tissue (400). We evaluated blad-
der cancer tissue as strong, and normal tissue as weak accord-
ing to our criteria.
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the Asp-Trp-Gly-Arg (NWGR) motif (3) and phos-
phorylation (22) are critical for the anti-apoptotic
function of galectin-3. Fukumori, et al . mentioned
that secreted extracellular galectin-3 was related to
pro-apoptotic function of galectin-3, but its mecha-
nisms are quite complicated and there are many un-
answerable questions (23).
The expression of galectin-3 is up-regulated in
various types of cancer. Several reports have indi-
cated its involvement in carcinogenesis (24, 25).
One possible reason for this is the anti-apoptotic
activity of galectin-3. Some reports have proposed
mechanisms by which galectin-3 protects cells from
apoptosis. Takenaka, et al. have shown that nuclear
export of galectin-3 is important for its anti-apoptotic
activity (26).
Galectin-3, which has been reported to be ex-
pressed in the nucleus, in the cytoplasm and on the
cell surface, can be secreted into the stroma (5). It
has been shown to be up-regulated in some cancers
such as thyroid carcinoma, hepatocellular carcinoma
and lymphoma, and down-regulated in others in-
cluding breast, uterine and pancreas cancer (27).
Expression pattern of galectin-3 is altered in many
types of cancers. Therefore, several attempts to use
galectin-3 expression as a diagnostic indicator are
under development. Inohara, et al. demonstrated
that expression of galectin-3 in fine needle aspirates
could be a diagnostic marker for thyroid cancer (28).
Aron, et al. mentioned that galectin-3 was strongly
expressed in smears of papillary thyroid carcinoma.
However, since it is also expressed in a variety of
benign lesions, its role as a pre-surgical marker
for differentiating benign from malignant thyroid
nodules is limited (29). Nakamura, et al. reported
that strong expression of galectin-3 in colorectal
cancer correlated with cancer progression, liver
metastasis, and poor prognosis for patients (30).
Shimamura, et al. studied decreased expression
of galectin-3 was associated with advanced stage,
tumor de-differentiation, and metastasis in ductal
adenocarcinoma of the pancreas (12).
The expression of galectin-3 is down-regulated
in some of urological cancers, suggesting that
galectin-3 has a tumor suppressive role in urologi-
cal organs. The mechanism by which galectin-3
promotes cancer progression has been reported.
However, little is known about tumor suppressive
functions of galectin-3 (31).
In prostate cancer, Van den Brule, et al. have re-
ported galectin-3 was usually not expressed or de-
creased compared with the normal glands (32). In
renal cell carcinoma, it has been shown galectin-3
expression was significantly higher in low-grade
conventional (clear cell) RCCs, indolent chromo-
phobe RCCs (33, 34).
On the contrary, Cindolo, et al. have reported
that increased galectin-3 mRNA expression com-
pared to basal levels of normal bladder samples was
observed in many bladder cancer samples with no
apparent correlation with the clinico-pathological
features such as stage and grade (13). We thought
if the role of galectin-3 could be solved clinically, it
was useful for diagnosis, prognostic prediction and
selection of anticancer therapies. Thus we tried to
measure the serum level of galectin-3 in bladder can-
cer patients.
We used ELISA kit to measure serum galectin-3
concentration in patients with bladder cancer. To
our knowledge, this is the first report using ELISA
kit to measure serum galectin-3 concentration in pa-
tients with bladder cancer. We demonstrated that
serum galectin-3 concentration in bladder cancer pa-
tients was statistically higher than normal control
patients (p0.0005).
However, there was no statistical difference in
either histological grade or pathological stage with
bladder cancer patients. Those results are consistent
with these as Cindolo, et al. has reported in vitro.
In immunohistochemical staining of galectin-3,
the expression of galectin-3 was apparently higher
in bladder cancer tissue than in normal bladder
tissue.
A standard method for diagnosis of bladder
cancer is urine cytology and cystoscopy. However,
cystoscopy is invasive and expensive. Several uri-
nary markers for bladder cancer have been inves-
tigated. Nuclear matrix protein-22 (NMP22), blad-
der tumor antigen (BTA) and urine cytology are
major urinary markers for diagnosis of bladder
cancer. Sensitivity and specificity were previously
reported with 85% and 91.3% for NMP22, 67% and
80.8% for BTA, 44% and 100% for urine cytology
(35). However, Poulakis, et al. have demonstrated
the specificity of urinary markers obviously became
low with pyuria in cystitis and urolithiasis (36). Con-
trary to urinary markers, serum level of galectin-3
is not affected by pyuria. For that reason we con-
sider that the measurement of serum galectin-3
will be helpful to diagnosis of bladder cancer, if blad-
der cancer is clinically suspected.
As the results of this study, the possibility that
galectin-3 will be useful in diagnosis of bladder can-
cer was suggested. However, there was no signifi-
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cant difference in the stage and grade in our study.
Further studies are needed to characterize the role
of galectin-3 in bladder cancer. We will examine the
level of urine galectin-3, and evaluate the utility
through a combination of serum galectin-3 and urine
markers including urine galectin-3. The combined
use of these markers might be able to improve ac-
curacy of diagnosis of bladder cancer.
In conclusion, the serum galectin-3 concentra-
tion of the bladder cancer patients was statistically
higher than that of controls. This result suggests
that the measurement of serum galectin-3 concen-
tration is helpful to diagnose bladder cancer.
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